Mobile

A single stage phase II, multi-centre, open label study of Glivec in combination with pioglitazone, etoricoxib, dexamethasone and low-dose treosulfane for anti-inflammatory and angiostatic treatment i...

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-000218-19

A single stage phase II, multi-centre, open label study of Glivec in combination with pioglitazone, etoricoxib, dexamethasone and low-dose treosulfane for anti-inflammatory and angiostatic treatment in patients with hormone-refractory prostate cancer

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To investigate the effect of a treatment with Imatinib mesylate (Glivec®), Pioglitazone (Actos®), Dexamethasone (Fortecortin®) and Etoricoxib (Arcoxia®) in combination with metronomic chemotherapy (Treosulfane: Ovastat®) on the PSA- response rate in patients with hormone refractory prostate cancer.

Critère d'inclusion

  • prostrate carcinoma

Liens